Drug Profile


Alternative Names: R 103757

Latest Information Update: 02 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Class Antihyperlipidaemics; Piperazines; Triazoles
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 17 Jun 2003 Discontinued - Phase-I for Hyperlipidaemia in Belgium (PO)
  • 29 Jul 1999 New profile
  • 29 Jul 1999 Phase-I clinical trials for Hyperlipidaemia in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top